Exact Sciences Corporation

NasdaqCM:EXAS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🩺 Medical Instruments

💻 Telehealth

Location

United States

Market Cap

USD 9.77 B

Share Price

USD 51.81

Avg Daily Volume

2,813,723

Change (1 day)

-0.21%

Change (1 year)

17.32%

Change (YTD)

-7.80%

Exact Sciences Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 2.83 B

Exact Sciences Corporation Revenue is USD 2.83 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 11.57% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Exact Sciences Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 2.53 B, a 15.21% change year over year.
Exact Sciences Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 2.20 B, a 18.83% change year over year.
Exact Sciences Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.85 B, a 19.79% change year over year.
Exact Sciences Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.55 B, a 45.53% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqCM: EXAS

Exact Sciences Corporation

CEO	Mr. Kevin T. Conroy J.D.
IPO Date	Feb. 1, 2001
Location	United States
Headquarters	5505 Endeavor Lane
Employees	6,900
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🩺 Medical Instruments 💻 Telehealth

Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.